-
ARIAD Pharmaceuticals, Inc. was an
American oncology company, now part of
Takeda Oncology,
which was
founded in 1991 by
Harvey J. Berger, M.D. and headquartered...
- others, is a small-molecule
targeted cancer therapy being developed by
Ariad Pharmaceuticals, Inc.
Brigatinib acts as both an
anaplastic lymphoma kinase...
- executive. He was the
founder and
chairman and
chief executive officer of
ARIAD Pharmaceuticals, Inc. for 25 years,
starting in 1991 and
became advisor...
-
venture along with
Lightstone Ventures. In
February 2017,
Takeda acquired Ariad Pharmaceuticals for $5.2 billion,
expanding the company's
oncology and hematology...
- chromosome–positive (Ph+)
acute lymphoblastic leukemia. It was
developed by
Ariad Pharmaceuticals. It is a multi-targeted tyrosine-kinase inhibitor. Some...
-
Ariad Pharmaceuticals et al. v. Eli
Lilly and Company, 598 F.3d 1336 (Fed. Cir. 2010) (en banc), is a
United States court case
regarding accusations of...
- sarcoma.
Ridaforolimus is
being co-developed by
Merck and
ARIAD Pharmaceuticals. On May 5, 2010,
Ariad Pharmaceuticals and
Merck &
Company announced a clinical...
- (2010–2024)
Antikamnia (1890–1930) ApothéCure (1991–2013)
Aptalis (2011–2014)
ARIAD (1991–2017)
Astra (1913–1999)
Aurora (1995–2001)
Australian Pharmaceutical...
-
mechanisms involved in
cancer and
brain development. He is a
founder of
Ariad Pharmaceuticals,
Amplyx Pharmaceuticals,
Foghorn Therapeutics, and Shenandoah...
-
mutation both to
imatinib and
second generations TKIs.
Ponatinib (Iclusig) by
Ariad was
approved in 2013 for use as second-line CML treatment, and is the only...
